The combination of gemcitabine and nab-paclitaxel in patients with locally advanced and advanced pancreatic cancer

L. Yu Vladimirova; Владимирова Л. Ю; N. A Abramova; Абрамова Н. А; I. L Popova; Попова И. Л; K. A Novoselova; Новоселова К. А; N. M Tikhanovskaya; Тихановская Н. М; L. A Ryadinskaya; Рядинская Л. А; A. A Lyanova; Льянова А. А; V. S Myagkova; Мягкова В. С; M. A Teplyakova; Теплякова М. А; A. E Storozhakova; Сторожакова А. Э; E. A Kalabanova; Калабанова Е. А; N. Yu Samaneva; Саманева Н. Ю; S. N Kabanov; Кабанов С. Н; Y. V Svetitskaya; Светицкая Я. В; A. V Tishina; Тишина А. В; L. K Strakhova; Страхова Л. К; M. O Yezhova; Ежова М. О

doi:10.18565/pharmateca.2020.7.53-57

The combination of gemcitabine and nab-paclitaxel in patients with locally advanced and advanced pancreatic cancer

Authors: Vladimirova L.Y.¹, Abramova N.A¹, Popova I.L¹, Novoselova K.A¹, Tikhanovskaya N.M¹, Ryadinskaya L.A¹, Lyanova A.A¹, Myagkova V.S¹, Teplyakova M.A¹, Storozhakova A.E¹, Kalabanova E.A¹, Samaneva N.Y.¹, Kabanov S.N¹, Svetitskaya Y.V¹, Tishina A.V¹, Strakhova L.K¹, Yezhova M.O¹
Affiliations:
1. National Medical Research Centre for Oncology
Issue: Vol 27, No 7 (2020)
Pages: 53-57
Section: Articles
URL: https://journals.eco-vector.com/2073-4034/article/view/312717
DOI: https://doi.org/10.18565/pharmateca.2020.7.53-57
ID: 312717

Cite item

Full Text

Open Access
Restricted Access

Access granted
Restricted Access

Subscription or Fee Access

Abstract
Full Text
About the authors
References
Supplementary files
Statistics

Abstract

Background. Nab-paclitaxel is a nanodispersed albumin-stabilized paclitaxel. This structure significantly changes the properties of paclitaxel, because albumin provides delivery and accumulation of paclitaxel in tumor tissue, and also affects its undesirable effects. Objective. Evaluation of the efficacy and safety of a combination of gemcitabine and nab-paclitaxel in patients with locally advanced and advanced pancreatic cancer. Methods. The data on treatment with nab-paclitaxel and gemcitabine in standard dosages in 23 patients with locally advanced and advanced pancreatic cancer were analyzed. The direct clinical effect, overall and progression-free survival, and adverse events associated with antitumor therapy were evaluated. Results. The objective antitumor effect (PR) was 26.1% (6), and 73.9% (17 patients) achieved tumor control (PR + CD). The median PFS was 6.0 months, OS - 9.7 months. The most common adverse events included neutropenia (34.7%), thrombocytopenia (34.7%), and anemia (43.5%). Non-hematologic toxicity was much less common. In some patients, complications led to the dose reduction (17.4%), delayed administration of cytostatics (17.3%), and discontinuation of therapy (4.3%). Conclusion Nab-paclitaxel in combination with gemcitabine has demonstrated clinical efficacy in the treatment of locally advanced and advanced pancreatic cancer, comparable to the results of international and retrospective Russian studies. This combination is characterized by a favorable toxicity profile and can be used, among others, in weakened patients with ECOG 2. It is necessary to carefully monitor non-hematological adverse events, because, despite their relative rarity, their severity and nature can significantly affect the treatment of patients with this severe oncopathology

Keywords

pancreatic cancer, chemotherapy, nab-paclitaxel, gemcitabine

Full Text

References

Аксель Е.М. Статистика злокачественных новообразований желудочно-кишечного тракта. Сибирский онкологический журнал 2017;16(3):5-11.
Покатаев И.А., Алиева С.Б., Гладков О.А. и др. Практические рекомендации по лекарственному лечению рака поджелудочной железы. Злокачественные опухоли: Практические рекомендации RUSSCO. 2019 (том 9). С. 456-468
Попова А.С., Покатаев И.А., Тюляндин С.А. Комбинированные режимы химиотерапии при раке поджелудочной железы. Медицинский совет. 2017;6:62-70
Alexis F, et al. Nanoparticle technologies for cancer therapy. Drug delivery Springer Berlin Heidelberg, 2010;197:55-86. doi: 10.1007/978-3-642- 00477-3_2.
Lammers T., et al. Tumour-targeted nanomedicines: principles and practice. Br J Cancer. 2008;99(3):392-97. Doi: 10.1038/ sj.bjc.6604483.
Von Hoff D.D., et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691-703. doi: 10.1056/NEJMoa1304369.
Conroy T., et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. Doi: 10.1056/ NEJMoa1011923.
Tabernero J., et al. Prognostic Factors of Survival in a Randomized Phase III Trial (MPACT) of Weekly nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone in Patients With Metastatic Pancreatic Cancer. Oncologist. 2015;20(2):143-50. doi: 10.1634/theoncologist.2014-0394.
Покатаев И.А., Лядова М.А., Федянин М.Ю., и др. Токсичность и эффективность комбинации гемцитабина и nab-паклитаксела (паклитаксел+альбумин) в российской популяции больных раком поджелудочной железы: результаты многоцентрового ретроспективного исследования. Злокачественные опухоли Российское общество клинической онкологии. 2019;9(3):20-31

Supplementary files

Supplementary Files

Action

1. JATS XML

Download

Username
Password
Remember me

Forgot password?	Register

Username
Password
Remember me

Forgot password?	Register

The combination of gemcitabine and nab-paclitaxel in patients with locally advanced and advanced pancreatic cancer

Full Text

Abstract

Keywords

Full Text

About the authors

References

Supplementary files

This website uses cookies